Jasper Therapeutics, Inc. (JSPR) Executive Compensation
Jasper Therapeutics, Inc. (JSPR) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: JSPR
CIK: 1788028
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2021 12:00:00 AM
Lead Engagement PartnerJeffrey Zechnich
Audit LocationSan Jose, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-15 | 2026-10-15 | CURRENT REPORT | 0001213900-26-109587 | View SEC Doc Filr Page |
| S-3 | 2026-10-14 | — | REGISTRATION STATEMENT | 0001213900-26-109479 | View SEC Doc Filr Page |
| PRE 14A | 2026-10-09 | 2026-10-09 | PROXY STATEMENT | 0001213900-26-108482 | View SEC Doc Filr Page |
| 8-K | 2026-10-07 | 2026-10-07 | CURRENT REPORT | 0001213900-26-107402 | View SEC Doc Filr Page |
| SC TO-I | 2026-10-07 | — | FORM SC TO-I | 0001213900-26-107397 | View SEC Doc Filr Page |
| 8-K | 2026-10-05 | 2026-09-30 | CURRENT REPORT | 0001213900-26-106651 | View SEC Doc Filr Page |
| 8-K/A | 2026-10-05 | 2026-07-16 | AMENDMENT NO. 2 TO FORM 8-K | 0001213900-26-106574 | View SEC Doc Filr Page |
| 8-K/A | 2026-10-01 | 2026-07-16 | AMENDMENT NO. 1 TO FORM 8-K | 0001213900-26-105924 | View SEC Doc Filr Page |
| 8-K | 2026-09-28 | 2026-09-23 | CURRENT REPORT | 0001213900-26-104101 | View SEC Doc Filr Page |
| 25-NSE | 2026-09-24 | — | 25-NSE Filing | 0001354457-26-000914 | View SEC Doc Filr Page |
| DEF 14A | 2026-09-04 | 2026-09-30 | PROXY STATEMENT | 0001213900-26-097572 | View SEC Doc Filr Page |
| 8-K | 2026-08-26 | 2026-08-21 | CURRENT REPORT | 0001213900-26-093979 | View SEC Doc Filr Page |
| PRE 14A | 2026-08-24 | 2026-08-24 | PROXY STATEMENT | 0001213900-26-093145 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-08-17 | — | SCHEDULE 13G Filing | 0000921895-26-002220 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-14 | CURRENT REPORT | 0001213900-26-090055 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-089592 | View SEC Doc Filr Page |
| D | 2026-08-05 | — | D Filing | 0001213900-26-085315 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-07-31 | 4 Filing | 0001213900-26-085192 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-07-31 | 4 Filing | 0001213900-26-085191 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-07-31 | 4 Filing | 0001213900-26-085190 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-07-31 | 4 Filing | 0001213900-26-085189 | View SEC Doc Filr Page |
| 4 | 2026-08-04 | 2026-07-31 | 4 Filing | 0001213900-26-085188 | View SEC Doc Filr Page |
| 8-K | 2026-08-03 | 2026-07-31 | CURRENT REPORT | 0001213900-26-084687 | View SEC Doc Filr Page |
| 8-K | 2026-07-31 | 2026-07-31 | CURRENT REPORT | 0001213900-26-083563 | View SEC Doc Filr Page |
| 3 | 2026-07-23 | 2026-07-16 | 3 Filing | 0001213900-26-080864 | View SEC Doc Filr Page |